A Phase 2 interventional study of Pemetrexed and Cetuximab in Head and Neck Neoplasms, sponsored by Eli Lilly and Company. Completed at 13 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-09-18.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing pemetrexed in Head and Neck Neoplasms — 1 open to participants now, 1 under way, none of them phase 3. Pemetrexed · Head and Neck Neoplasms.
Among the 13 studies testing pemetrexed in Head and Neck Neoplasms, this one is the 4th largest by enrollment, is one of 2 that started in 2010, is one of 8 in phase 2, and was the 8th registered.
2,714 studies on the registry are indexed under Head and Neck Neoplasms; 597 are open to participants now.
Browse Head and Neck Neoplasms studies →1 of the 13 studies testing pemetrexed in Head and Neck Neoplasms is open now, in 1 country. Recruiting first, the newest first:
Rutgers, The State University of New Jersey · Sites in United States
Ages 18+
By country, each count listing its studies:
Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 456 Head and Neck Neoplasms studies recruiting now, 348 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 66 is above the median of 46 across 2,033 interventional studies indexed under Head and Neck Neoplasms.
Median enrollment 36 across the 13 interventional studies. Of the 12 that completed or were terminated, 7 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 13 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
14 studies in Head and Neck Neoplasms by Eli Lilly and Company: 1 open now, 3 under way, none of them phase 3. Of 11 finished, 9 (82%) have results posted.
Among the 14 studies in Head and Neck Neoplasms by Eli Lilly and Company, this one is the 9th largest by enrollment of the 13 interventional ones that give a count, is one of 5 that started in 2010, is one of 7 in phase 2, and was the 4th registered.
Eli Lilly and Company’s Head and Neck Neoplasms studies by the year they started, since 2005.
1 of the studies testing pemetrexed in Head and Neck Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05358548Rutgers, The State University of New JerseyATATcH Alternating Treatment Plans for Advanced Cancer | 2027-05-01 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies testing pemetrexed in Head and Neck Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 14 in Head and Neck Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is to estimate progression free survival in patients with recurrent or metastatic head and neck cancer that have not received chemotherapy in this setting.
A 12 patient safety lead will evaluate side effects in patients receiving at least 2 cycles of the combination pemetrexed, cisplatin and cetuximab.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive pemetrexed,cisplatin and cetuximab for up to 6 cycles (21 days per cycle) followed by optional maintenance of pemetrexed and cetuximab until disease progression. Optional maintenance therapy is permitted after at least 4 cycles of triplet combination therapy have been given. Cetuximab will be administered as an initial dose of 400 milligram per meter squared (mg/m\^2) intravenous (IV) infusion and as a 250 mg/m\^2 IV weekly dose thereafter. As Standard of care dietary supplements included: 350 to 1000 micrograms (µg) oral Folic Acid 5 times a day for the 7 days preceding the first dose of first dose of pemetrexed and continuing throughout treatment and for 21 days after the last dose of pemetrexed and 1000 µg vitamin B12 intramuscular injection (IM) during the week preceding the first dose of pemetrexed and every 9 weeks thereafter.
Drug: Pemetrexed · Drug: Cetuximab · Drug: Cisplatin · Dietary Supplement: Folic Acid · Dietary Supplement: Vitamin B12
Triplet Combination Therapy: 500 mg/m\^2 administered intravenously on Day 1 of 21 day cycle for up to 6 cycles Maintenance Therapy: 500mg/m\^2 administered intravenously on Day 1 of 21 day cycle until disease progression or unacceptable toxicity
Also known as: Alimta, LY231514
Triplet Combination Therapy: 400 mg/m\^2 administered intravenously on Day 1 of 21 day cycle for 1 cycle; 250 mg/m\^2 administered IV infusion on Day 1 of 21 day cycle and then weekly for up to 6 cycles. Maintenance Therapy: 250 mg/m\^2 administered intravenously on Day 1 of 21 day cycle and then weekly until disease progression or unacceptable toxicity
Triplet Combination Therapy: 75mg/m\^2 administered intravenously on Day 1 of 21 day cycle for up to 6 cycles.
Standard of care dietary supplements: 350 to 1000 µg orally 5 times a day for the 7 days preceding the first dose of first dose of pemetrexed and continuing throughout treatment and for 21 days after the last dose of pemetrexed.
Standard of care dietary supplements: 1000 µg IM during the week preceding the first dose of pemetrexed and every 9 weeks thereafter.
Progression Free Survival (PFS)
PFS based on Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines defined as the time from the date of first dose of study drug to first documented objective progressive disease (PD) or death from any cause. PD is defined as at least a 20% increase in the sum of longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
Time frame: Baseline to date of PD or death up to 18.7 months
Overall Survival (OS)
OS defined as the time from the date of first dose of study drug to the date to death from any cause.
Time frame: Baseline to date of death up to 18.7 months
Percent of Participants With a Partial Response (PR) or a Complete Response (CR)
CR and PR based on RECIST Guidelines: CR is defined as the disappearance of all tumor lesions; PR is defined as at least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LDs or the complete disappearance of target lesions, with persistence (but not worsening) of one or more nontarget lesions and the appearance of no new lesions. PD is defined as at least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
Time frame: Date of first response to PD (up to 18.7 months)
Change From Baseline in Participant Reported European-Quality of Life 5 Dimension Instrument (EQ-5D) Visual Analog Scale (VAS) at End of Triplet Combination Therapy and End of Maintenance Therapy
Vertical VAS - a 20 millimeter (mm), fractionated scale in the form of a thermometer with endpoints of 0 (worst imaginable health state) and 100 (best imaginable health state). Participants used the EQ-5D VAS scale to rate their overall health on the day the questionnaire was administered. Possible change values range from -100 (best imaginable health at baseline changed to worst possible health at visit) to 100 (worst possible health at baseline changed to best possible health at visit).
Time frame: Baseline, End of Triplet Combination Therapy (up to Cycle 6 [4.2 months]), End of Maintenance Therapy (up to 18.7 months)
Change From Baseline in Participant Reported EQ-5D Utility Score at End of Triplet Combination Therapy and End of Maintenance Therapy
EQ-5D Index is derived by converting the Descriptive System (participant is required to rate health by checking 1 \[no limitation\], 2 \[some limitation\] or 3 \[severe or complete limitation\] in 5 dimensions \[mobility, self-care, usual activities, pain/comfort and anxiety/depression\]) to a single summary index. A utility value assigned to each individual's health state based on the absence or presence of moderate or severe problems in the 5 dimensions. A regression equation defines a utility value for these health states. The possible values for health utility ranged from -0.59 (severe problems in all 5 dimensions) to 1 (no problem in all dimensions) on a scale where 0 represents death and 1 represents the best possible health state. Possible change values range from -1.59 (no problems at baseline to severe problems at visit) to 1.59 (severe problems at baseline to no problems at visit).
Time frame: Baseline, End of Triplet Combination Therapy (up to 6 cycles [4.2 months]) , End of Maintenance Therapy (up to 18.7 months)
Change From Baseline in Performance Status Scale for Head and Neck Cancer Patients (PSS-HNC)
PSS-HNC is a clinician-rated instrument designed to measure speaking and eating disabilities of participants with head and neck cancer and consists of 3 subscales: Normalcy of Diet (NOD) subscale measures the ability of the participants to eat a normal diet, scale ranged from 0 (non-oral feeding) to 100 (unrestricted diet); Understandability of Speech (UOS)subscale measured the degree a clinician was able to understand the participant's speech, subscale ranged from 0 (never understandable) to 100 (always understandable); Eating in Public (EIP) subscale, rating based on clinician question to the participant to report who he/she eats with and in what setting, subscale ranged from 0 (always eats alone) to 100 (no restriction of place, food, or companion). Change from baseline: negative value represents a decrease in function and a positive value represents an increase in function.
Time frame: Baseline, Triplet Combination Therapy Cycles 2, 4, 6 (cycle = 21 days) and optional Maintenance Therapy Cycles 1, 3, 5 and 7 (cycle = 21 days)
| Milestone | Pemetrexed + Cisplatin + Cetuximab |
|---|---|
| Started | 66 |
| Completed | 0 |
| Not completed | 66 |
| Withdrew: Disease progression | 35 |
| Withdrew: Adverse event | 10 |
| Withdrew: Physician decision | 8 |
| Withdrew: Withdrawal by subject | 3 |
| Withdrew: Sponsor decision | 1 |
| Withdrew: Death | 8 |
| Withdrew: Lost to follow-up | 1 |
PFS based on Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines defined as the time from the date of first dose of study drug to first documented objective progressive disease (PD) or death from any cause. PD is defined as at least a 20% increase in the sum of longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
| months | Pemetrexed Cisplatin Cetuximab |
|---|---|
| Progression Free Survival (PFS) | 4.4 (3.6 to 5.4) |
OS defined as the time from the date of first dose of study drug to the date to death from any cause.
| months | Pemetrexed Cisplatin Cetuximab |
|---|---|
| Overall Survival (OS) | 9.7 (6.5 to 13.1) |
CR and PR based on RECIST Guidelines: CR is defined as the disappearance of all tumor lesions; PR is defined as at least a 30% decrease in the sum of the LD of target lesions taking as reference the baseline sum LDs or the complete disappearance of target lesions, with persistence (but not worsening) of one or more nontarget lesions and the appearance of no new lesions. PD is defined as at least a 20% increase in the sum of LD of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.
| percentage of participants | Pemetrexed Cisplatin Cetuximab |
|---|---|
| Percent of Participants With a Partial Response (PR) or a Complete Response (CR) | 29.3 (18.1 to 42.7) |
Vertical VAS - a 20 millimeter (mm), fractionated scale in the form of a thermometer with endpoints of 0 (worst imaginable health state) and 100 (best imaginable health state). Participants used the EQ-5D VAS scale to rate their overall health on the day the questionnaire was administered. Possible change values range from -100 (best imaginable health at baseline changed to worst possible health at visit) to 100 (worst possible health at baseline changed to best possible health at visit).
| units on a scale | Pemetrexed Cisplatin Cetuximab |
|---|---|
| Change at End of Triplet Therapy (n=23) | -1.2 ± 14.28 |
| Change at End of Maintenance Therapy (n=11) | -10.6 ± 21.51 |
EQ-5D Index is derived by converting the Descriptive System (participant is required to rate health by checking 1 \[no limitation\], 2 \[some limitation\] or 3 \[severe or complete limitation\] in 5 dimensions \[mobility, self-care, usual activities, pain/comfort and anxiety/depression\]) to a single summary index. A utility value assigned to each individual's health state based on the absence or presence of moderate or severe problems in the 5 dimensions. A regression equation defines a utility value for these health states. The possible values for health utility ranged from -0.59 (severe problems in all 5 dimensions) to 1 (no problem in all dimensions) on a scale where 0 represents death and 1 represents the best possible health state. Possible change values range from -1.59 (no problems at baseline to severe problems at visit) to 1.59 (severe problems at baseline to no problems at visit).
| units on a scale | Pemetrexed Cisplatin Cetuximab |
|---|---|
| Change at End of Triplet Therapy (n=29) | 0.05 ± 0.230 |
| Change at End of Maintenance Therapy (n=15) | -0.02 ± 0.291 |
PSS-HNC is a clinician-rated instrument designed to measure speaking and eating disabilities of participants with head and neck cancer and consists of 3 subscales: Normalcy of Diet (NOD) subscale measures the ability of the participants to eat a normal diet, scale ranged from 0 (non-oral feeding) to 100 (unrestricted diet); Understandability of Speech (UOS)subscale measured the degree a clinician was able to understand the participant's speech, subscale ranged from 0 (never understandable) to 100 (always understandable); Eating in Public (EIP) subscale, rating based on clinician question to the participant to report who he/she eats with and in what setting, subscale ranged from 0 (always eats alone) to 100 (no restriction of place, food, or companion). Change from baseline: negative value represents a decrease in function and a positive value represents an increase in function.
| units on a scale | Pemetrexed Cisplatin Cetuximab |
|---|---|
| NOD-Change at Triplet Cycle 2 (n=53) | -0.4 ± 20.8 |
| NOD-Change at Triplet Cycle 4 (n=41) | 3.9 ± 24.2 |
| NOD-Change at Triplet Cycle 6 (n=24) | 3.3 ± 23.5 |
| NOD-Change at Maintenance Cycle 1 (n=23) | 0.4 ± 29.9 |
| NOD-Change at Maintenance Cycle 3 (n=10) | -1.0 ± 21.3 |
| NOD-Change at Maintenance Cycle 5 (n=6) | 8.3 ± 20.4 |
| NOD-Change at Maintenance Cycle 7 (n=5) | -8.0 ± 11.0 |
| EIP-Change at Triplet Cycle 2 (n=46) | 2.7 ± 25.4 |
| EIP-Change at Triplet Cycle 4 (n=37) | -6.8 ± 29.3 |
| EIP-Change at Triplet Cycle 6 (n=22) | -3.4 ± 20.8 |
| EIP-Change at Maintenance Cycle 1 (n=23) | -8.7 ± 38.1 |
| EIP-Change at Maintenance Cycle 3 (n=10) | -10.0 ± 21.1 |
| EIP-Change at Maintenance Cycle 5 (n=6) | -4.2 ± 24.6 |
| EIP-Change at Maintenance Cycle 7 (n=5) | -15.0 ± 22.4 |
| UOS-Change at Triplet Cycle 2 (n=53) | 0.5 ± 18.0 |
| UOS-Change at Triplet Cycle 4 (n=41) | -4.3 ± 17.6 |
| UOS-Change at Triplet Cycle 6 (n=24) | -10.4 ± 22.0 |
| UOS-Change at Maintenance Cycle 1 (n=23) | -1.1 ± 14.1 |
| UOS-Change at Maintenance Cycle 3 (n=10) | -2.5 ± 7.9 |
| UOS-Change at Maintenance Cycle 5 (n=6) | -12.5 ± 34.5 |
| UOS-Change at Maintenance Cycle 7 (n=5) | -15.0 ± 33.5 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pemetrexed Cisplatin Cetuximab | — | 45/66 (68.2%) | 65/66 (98.5%) |
| Event | Pemetrexed Cisplatin Cetuximab |
|---|---|
| PneumoniaInfections and infestations | 7/66 |
| HypotensionVascular disorders | 5/66 |
| AnaemiaBlood and lymphatic system disorders | 4/66 |
| DiarrhoeaGastrointestinal disorders | 4/66 |
| Febrile neutropeniaBlood and lymphatic system disorders | 3/66 |
| LeukopeniaBlood and lymphatic system disorders | 3/66 |
| NeutropeniaBlood and lymphatic system disorders | 3/66 |
| PyrexiaGeneral disorders | 3/66 |
| Respiratory tract infectionInfections and infestations | 3/66 |
| Decreased appetiteMetabolism and nutrition disorders | 3/66 |
| Event | Pemetrexed Cisplatin Cetuximab |
|---|---|
| FatigueGeneral disorders | 40/66 |
| RashSkin and subcutaneous tissue disorders | 31/66 |
| Decreased appetiteMetabolism and nutrition disorders | 29/66 |
| NauseaGastrointestinal disorders | 27/66 |
| AnaemiaBlood and lymphatic system disorders | 26/66 |
| LeukopeniaBlood and lymphatic system disorders | 26/66 |
| NeutropeniaBlood and lymphatic system disorders | 26/66 |
| ConstipationGastrointestinal disorders | 25/66 |
| VomitingGastrointestinal disorders | 22/66 |
| Mucosal inflammationGeneral disorders | 22/66 |
| Age Continuous(years) | Pemetrexed Cisplatin Cetuximab |
|---|---|
| Mean | 61.8 ± 9.56 |
| Sex: Female, Male(Participants) | Pemetrexed Cisplatin Cetuximab |
|---|---|
| Female | 13 |
| Male | 53 |
| Race/Ethnicity, Customized(participants) | Pemetrexed Cisplatin Cetuximab |
|---|---|
| White | 66 |
| Region of Enrollment(participants) | Pemetrexed Cisplatin Cetuximab |
|---|---|
| Belgium | 8 |
| France | 4 |
| Germany | 32 |
| Italy | 8 |
| Spain | 13 |
| United Kingdom | 1 |
The record gives a start of Feb 2010, a primary completion of Feb 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2013, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pemetrexed · Cetuximab · Cisplatin